Treatments of Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection: Treat HBV-related HCC

AIMS Medical Science

article

Charing Ching-Ning Chong¹  Grace Lai-Hung Wong¹ 

[1] Institute of Digestive Disease, The Chinese University of Hong Kong;Department of Surgery, The Chinese University of Hong Kong;Department of Medicine and Therapeutics, The Chinese University of Hong Kong;State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong

关键词: hepatitis B;    HBV DNA;    hepatocellular carcinoma;    cirrhosis;    lamivudine;    entecavir;    tenofovir;    interferon;    sorafenib;    sirolimus;    ;   

DOI  :  10.3934/medsci.2016.1.162

来源: American Institute of Mathematical Sciences

【 摘 要 】

There have been major advances recently on the therapeutic approaches of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Surgical treatments are the key curative treatments of HCC, whereas local ablative treatments may also achieve clinical remission in selected cases. Trans-arterial locoregional therapies are regarded as palliative but still lead to improved survival. There have been major breakthroughs in the systemic therapies for HCC. The first marketed targeted therapy, sorafenib, was shown to improve survival in patients with advanced HCC. Studies on other targeted therapies also showed promising results. Suppressing HBV with effective antiviral treatment would also benefit HCC patients by reducing recurrence and improving liver function.

【 授权许可】

CC BY